Management of serious staphylococcal infections in the outpatient setting

Drugs

Volumn 54, Issue SUPPL. 6, 1997, Pages 21-28

  Graninger, W ^a   Presterl, E ^a   Wenisch, C ^a   Schwameis, E ^a   Breyer, S ^a   Vukovich, T ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; TEICOPLANIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; CHRONIC OSTEOMYELITIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FEVER; ENDOCARDITIS; FEMALE; HEARING IMPAIRMENT; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; OSTEOMYELITIS; OUTPATIENT; PSEUDOMEMBRANOUS COLITIS; RASH; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCI; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0031442385     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199700546-00006     Document Type: Article

References (23)

1. 1. JM Eisenberg DS Kitz 1986 Savings from outpatient antibiotic therapy for osteomyelitis: economic analysis of a therapeutic strategy JAMA 255 1584 3951094 10.1001/jama.1986.03370120062024 1:STN:280:DyaL287ksVaisQ%3D%3D Eisenberg JM, Kitz DS. Savings from outpatient antibiotic therapy for osteomyelitis: economic analysis of a therapeutic strategy. JAMA 1986; 255: 1584
2. 2. E Rubinstein A Barzilai S Segey 1988 Antibiotic cost reduction by providing cost information Eur J Clin Pharmacol 35 269 72 3181280 10.1007/BF00558264 1:STN:280:DyaL1M%2FjtV2ntA%3D%3D Rubinstein E, Barzilai A, Segey S, et al. Antibiotic cost reduction by providing cost information. Eur J Clin Pharmacol 1988; 35: 269–72
3. 3. DM Poretz 1991 Home intravenous therapy Clin Geriatr Med 7 749 1760792 1:STN:280:DyaK387gtlGqsQ%3D%3D Poretz DM. Home intravenous therapy. Clin Geriatr Med 1991; 7: 749
4. 4. GR Kravitz 1993 Advances in iv delivery Hosp Pract 28 1 21 Kravitz GR. Advances in iv delivery. Hosp Pract 1993; 28 Suppl. 1: 21
5. 5. AD Tice 1996 Outpatient parenteral antibiotic therapy in different countries Int Infect Dis 1 102 6 10.1016/S1201-9712(96)90063-6 Tice AD. Outpatient parenteral antibiotic therapy in different countries. Int Infect Dis 1996; 1: 102–6
6. 6. G Milkovich 1995 Benefits of outpatient parenteral therapy: to the individual, the institution, third-party payers and society Int J Antimicrob Agents 5 27 31 18611642 10.1016/0924-8579(94)00049-Z 1:CAS:528:DyaK2MXjsVOlsbw%3D Milkovich G. Benefits of outpatient parenteral therapy: to the individual, the institution, third-party payers and society. Int J Antimicrob Agents 1995; 5: 27–31
7. 7. RN Grüneberg 1997 Anti-Gram-positive agents: what we have and what we would like Drugs 54 6 29 38 9474479 10.2165/00003495-199700546-00007 Grüneberg RN. Anti-Gram-positive agents: what we have and what we would like. Drugs 1997; 54 Suppl. 6: 29–38
8. 8. APR Wilson RN Grüneberg H Neu 1994 A critical review of the dosage of teicoplanin in Europe and the USA Int J Antimicrob Agents 4 1 1 30 18611626 10.1016/0924-8579(94)90049-3 Wilson APR, Grüneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994; 4 Suppl. 1: 1–30
9. 9. APR Wilson RN Grüneberg 1994 Use of teicoplanin in community medicine Eur J Clin Microbiol Infect Dis 13 701 10 7843174 10.1007/BF02276052 1:STN:280:DyaK2M7ksFCltg%3D%3D Wilson APR, Grüneberg RN. Use of teicoplanin in community medicine. Eur J Clin Microbiol Infect Dis 1994; 13: 701–10
10. 10. P Calain KH Krause P Vaudaux 1987 Early termination of a prospective randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections J Infect Dis 155 187 91 2949024 10.1093/infdis/155.2.187 1:STN:280:DyaL2s7htVyhuw%3D%3D Calain P, Krause KH, Vaudaux P, et al. Early termination of a prospective randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis 1987; 155: 187–91
11. 11. JL Frock Le AM Ristuccia RW Quenzer 1992 Teicoplanin in the treatment of bone and joint infections Eur J Surg 567 9 13 Le Frock JL, Ristuccia AM, Quenzer RW, et al. Teicoplanin in the treatment of bone and joint infections. Eur J Surg 1992; 567 Suppl.: 9–13
12. 12. PG Davey DR Rowley GA Phillips 1992 Teicoplanin — home therapy for prosthetic joint infections Eur J Surg 567 23 5 Davey PG, Rowley DR, Phillips GA. Teicoplanin — home therapy for prosthetic joint infections. Eur J Surg 1992; 567 Suppl.: 23–5
13. 13. W Graninger C Wenisch E Wiesinger 1995 Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis Eur J Clin Microbiol Infect Dis 14 643 7 7588858 10.1007/BF01690746 1:CAS:528:DyaK2MXpsVWltbw%3D Graninger W, Wenisch C, Wiesinger E, et al. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1995; 14: 643–7
14. 14. A Karchmer 1985 Staphylococcal endocarditis Am J Med 78 116 27 3893113 10.1016/0002-9343(85)90374-2 1:STN:280:DyaL2M3kvVGnsA%3D%3D Karchmer A. Staphylococcal endocarditis. Am J Med 1985; 78 Suppl.: 116–27
15. 15. E Presterl W Graninger A Georgopoulos 1993 The efficacy of teicoplanin in the treatment of endocarditis caused by Gram positive bacteria J Antimicrob Chemother 31 755 66 8335503 10.1093/jac/31.5.755 1:STN:280:DyaK3szivVGiug%3D%3D Presterl E, Graninger W, Georgopoulos A. The efficacy of teicoplanin in the treatment of endocarditis caused by Gram positive bacteria. J Antimicrob Chemother 1993; 31: 755–66
16. 16. DN Gilbert CA Wood RC Kimbough 1991 Failure of treatment with teicoplanin at 6 mg/kg/day in patients with Staphylococcus aureus intravascular infection Antimicrob Agents Chemother 35 79 87 1826594 10.1128/AAC.35.1.79 1:STN:280:DyaK3M7pslSqtA%3D%3D Gilbert DN, Wood CA, Kimbough RC. Failure of treatment with teicoplanin at 6 mg/kg/day in patients with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother 1991; 35: 79–87
17. 17. P Francioli J Etienne R Hoigné 1992 Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks JAMA 267 264 7 1727524 10.1001/jama.1992.03480020074034 1:STN:280:DyaK38%2FosFCltA%3D%3D Francioli P, Etienne J, Hoigné R, et al. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. JAMA 1992; 267: 264–7
18. 18. EP Moore DCE Speller 1988 In vitro teicoplanin-resistance in coag-ulase-negative staphylococci from patients with endocarditis and from a cardiac surgery unit J Antimicrob Chemother 21 417 24 2967810 10.1093/jac/21.4.417 1:STN:280:DyaL1c3ktlGrsQ%3D%3D Moore EP, Speller DCE. In vitro teicoplanin-resistance in coag-ulase-negative staphylococci from patients with endocarditis and from a cardiac surgery unit. J Antimicrob Chemother 1988; 21: 417–24
19. 19. A Marchese EA Debbia D Bacca 1997 Multidrug-resistant Gram-positive pathogens: an update on current microbiological patterns Drugs 54 6 11 20 9474477 10.2165/00003495-199700546-00005 Marchese A, Debbia EA, Bacca D, et al. Multidrug-resistant Gram-positive pathogens: an update on current microbiological patterns. Drugs 1997; 54 Suppl. 6: 11–20
20. 20. Grüneberg RN, Harding I. A review of the clinical and bacteriological efficacy of teicoplanin against coagulase-negative staphylococci. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 25–28; Lausanne
21. 21. PG Davey AH Williams 1991 A review of the safety profile of teicoplanin J Antimicrob Chemother 27 B 69 73 1829079 10.1093/jac/27.suppl_B.69 Davey PG, Williams AH. A review of the safety profile of teicoplanin. J Antimicrob Chemother 1991; 27: Suppl. B: 69–73
22. 22. C Wenisch E Etzersdorfer S Breyer 1994 Intravenous teicoplanin does not prevent Clostridium difficile associated diarrhea Clin Investig 72 922 4 7894224 10.1007/BF00190753 1:STN:280:DyaK2M3gtFGjsg%3D%3D Wenisch C, Etzersdorfer E, Breyer S, et al. Intravenous teicoplanin does not prevent Clostridium difficile associated diarrhea. Clin Investig 1994; 72: 922–4
23. 23. PG Davey R South M Malek 1996 Impact of glycopeptide therapy after hospital discharge on inpatients costs: a comparison of teicoplanin and vancomycin J Antimicrob Chemother 37 623 34 9182120 10.1093/jac/37.3.623 1:CAS:528:DyaK28XitValsrc%3D Davey PG, South R, Malek M. Impact of glycopeptide therapy after hospital discharge on inpatients costs: a comparison of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 623–34